Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) | Region

MILAN--(BUSINESS WIRE)--Apr 8, 2024--

Related Keywords

Canada ,Milan ,Lombardia ,Italy ,Switzerland ,Seika ,Kyongsang Bukto ,South Korea ,India ,United Kingdom ,Sri Lanka ,United States ,United Arab Emirates ,Bresso ,Australia ,Israel ,Japan ,Swiss ,America ,Stefan Weber ,Paul Sagan ,Anne Hennecke Caroline Bergmann ,Valentin Handschin ,Dusseldorf Stock Exchange ,Newron Pharmaceuticals ,Mc Services ,European Union ,Supernus Pharmaceuticals ,Swiss Exchange ,Schizophrenia International Research Society ,Negative Syndrome Scale ,Clinical Global Impression ,Strauss Carpenter Level ,Latin America ,Meiji Seika ,Ciara Martin ,Natalie Garland Collins ,Caroline Bergmann ,Business Wire ,